admin – Page 2699 – Get News Story

WebTech Solutions Revolutionizes Digital Marketing with Comprehensive Services

The trustworthy digital marketing services offered by WebTech Solutions are meant to help brands grow in the digital world. WebTech Solutions specialises in Search Engine Optimisation (SEO), Social Media Marketing, Content Marketing, and Link Building. Their goal is to help their clients achieve maximum growth and success by creating personalised and effective digital strategies.

WebTech Solutions stays ahead of the curve in the digital marketing business by providing cutting edge digital solutions that are customised to meet the specific needs of each client.

Establishing in UAE and USA

WebTech Solutions is thrilled to announce the opening of new offices in the USA and the UAE as part of a strategic plan to increase its global presence. The goal of this development is to give businesses in these areas localised support and services so they can confidently survive and thrive in the digital realm. WebTech Solutions is dedicated to providing outstanding digital marketing solutions that are customised to meet the specific requirements of clients in the USA and the UAE by forging a presence in these commercial hubs.

Key Services Offered by WebTech Solutions

Search Engine Optimisation (SEO): Comprehensive SEO strategies that improve website visibility and organic search rankings.

Social Media Marketing: Targeted social media campaigns that boost brand presence and build customer relationships.

Content Marketing: Creation and distribution of valuable content that attracts and engages the target audience.

Link Building: Strategic link-building initiatives that increase website authority and drive referral traffic.

“At WebTech Solutions, we believe in empowering businesses of all types by providing them with the marketing solutions and strategies needed to succeed in this modern world,” said Fawad Malik, CEO of WebTech Solutions. “Our comprehensive approach to digital marketing ensures that our clients achieve their goals and stay ahead of the competition.”

About Fawad Malik

The CEO of WebTech Solutions, Fawad Malik, is a well-known player in the digital marketing field. Fawad has built WebTech Solutions into a trusted digital partner for companies all over the world with more than 12 years of experience and passion for new ideas. Aside from being the leader at WebTech Solutions, Fawad also started Nogentech.org, a technology blog that tech geeks can trust to get useful information, latest updates and ideas about technology, digital marketing, and other topics. The Nogentech blog has a loyal readership and is recognized for its informative content and practical advice.

For more information about WebTech Solutions and its services, please visit www.webtechsolution.org

Media Contact
Company Name: WebTech Solutions
Contact Person: Fawad Malik
Email: Send Email
City: Faisalabad
Country: Pakistan
Website: http://www.webtechsolution.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: WebTech Solutions Revolutionizes Digital Marketing with Comprehensive Services

The Crowned Company: How Damian Griggs Merges Divinity with Business Discipline

In a business world addicted to hustle and hollow mission statements, Damian Griggs is building something very different: a company founded on spiritual alignment, precision execution, and nature’s laws of balance and acceleration.

The Griggs Model isn’t a theoretical playbook or lifestyle brand—it’s an operating system that treats clarity as currency and discipline as leverage. At its core is a philosophy most startups miss: true success isn’t just about scale, it’s about sovereignty.

“Speed without distortion. Growth without burnout. Leadership without ego,” says Griggs. “If you’re not aligned internally, nothing you build will last externally. Nature teaches that. And business should follow.”

The Problem the Griggs Model Solves

Modern businesses are collapsing under their own weight. Founders burn out. Teams misfire. Cultures rot behind smiling Slack emojis. What most companies call “leadership” is often just stress-fueled reaction in a suit. Strategy becomes survival. Vision becomes noise.

The problem isn’t a lack of ideas or ambition. It’s misalignment.

Companies scale before they stabilize. Founders execute without clarity. Burnout gets mistaken for momentum. In that chaos, energy is wasted—and results become brittle.

The Griggs Model addresses this breakdown at the root: by demanding that internal alignment comes before external expansion. It forces leaders to confront whether their business, their systems, and their teams are in resonance—or just in motion.

Where other models optimize speed, this one prioritizes clean signal. Where others chase revenue, this one ensures the structure can hold it. It’s not about doing more. It’s about becoming clear enough that what you do actually works.

The Profit Advantage: Why the Griggs Model Wins

At its core, the Griggs Model is about one thing: efficient profitability through disciplined execution. Every piece of the framework is designed to eliminate waste, increase leverage, and multiply output—without compromising the founder’s energy or the company’s long-term vision.

Here’s how it works:

– Outsource everything except leadership and core IP. This trims overhead, accelerates response time, and prevents managerial bloat.
– Reward output, not appearances. Performance-based pay, innovation bounties, and quarterly pruning ensure only high-leverage contributors remain.
– Conquer through profit. Surplus is reinvested into acquisitions, not vanity. The model turns margin into momentum.
– Decide with clarity. Founders make final calls without bureaucracy—but with intention and accountability.
– Localize tactics. Centralize strategy. Regional teams execute with cultural fluency under a unified playbook.

The result? Higher margins. Faster cycles. More adaptable teams. Lower churn.

In a business world paralyzed by overthinking, the Griggs Model rewards clean execution. And when your systems are aligned and your team is streamlined, profitability isn’t just possible—it becomes inevitable.

Why Alignment Is the Next Competitive Advantage

Most companies spend fortunes trying to patch inefficiency with perks, tech stacks, or consultants. But none of that works if the core is misaligned.

The future doesn’t belong to the loudest voice or the fastest funding round. It belongs to the builders who know how to keep their signal clean.

That’s what the Griggs Model delivers: a way to align the founder, the team, and the execution layer so that energy compounds instead of leaks.

Alignment doesn’t slow you down. It removes friction. It doesn’t reject profit. It supercharges it.

The next great companies won’t just move fast. They’ll move clean. And when they do, they won’t just win—they’ll lead in a way that actually lasts.

About the Author

Damian Griggs is a strategic advisor and founder of a business operating model rooted in clarity, execution, and energetic alignment. His framework is currently being implemented while working with a local business to scale efficiently, reduce waste, and build long-term enterprise value. For inquiries or advisory opportunities, contact: dgriggsde@gmail.com.

Or follow on Twitter / x:

https://x.com/damianwgriggs?t=6bIwcRBpsVRauepP6rMz1A&s=09

Media Contact
Company Name: Damian Griggs,Strategic Advisor
Contact Person: Damian Griggs
Email: Send Email
Country: United States
Website: https://x.com/damianwgriggs?t=6bIwcRBpsVRauepP6rMz1A&s=09

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Crowned Company: How Damian Griggs Merges Divinity with Business Discipline

Northwest Exteriors Encourages Homeowners to Upgrade with High-Performance Replacement Windows

Rancho Cordova, CA – Northwest Exteriors, a leader in residential home improvement, is urging California and Hawaii homeowners to take advantage of the benefits offered by modern replacement windows. With the latest in energy-efficient technology, Northwest Exteriors’ window solutions are designed to enhance comfort, boost curb appeal, and reduce utility bills year-round.

As outdated windows contribute to energy loss, rising utility costs, and reduced home value, investing in new replacement windows is a smart and timely upgrade. Northwest Exteriors offers a full range of styles, materials, and performance features to meet the needs of every homeowner, from Santa Rosa and Sacramento to Kapolei, HI.

Key benefits of Northwest Exteriors’ replacement windows include:

Advanced Energy Efficiency: Dual- and triple-pane options with low-E coatings to reduce heat transfer.
UV Protection: Helps preserve interior furnishings by blocking harmful ultraviolet rays.
Noise Reduction: Enhanced insulation provides quieter indoor environments.
Custom Designs: A wide variety of frame colors, hardware finishes, and styles to match any home.
Professional Installation: Trusted craftsmanship from experienced technicians ensures lasting results.

“Homeowners don’t always realize how much energy and comfort they lose through outdated windows,” said a spokesperson for Northwest Exteriors. “Our replacement windows offer a simple, effective way to upgrade a home’s performance and appearance.”

With decades of experience and a reputation for superior service, Northwest Exteriors makes the replacement process easy with personalized consultations, detailed project planning, and financing options for qualified homeowners.

Schedule a Free Window Consultation Today

Now is the time to improve your home with energy-efficient replacement windows from Northwest Exteriors. Visit northwestexteriors.com/windows to browse styles and schedule your free estimate.

About Northwest Exteriors

Northwest Exteriors is a trusted provider of high-quality new and replacement windows, doors, patio covers, sunrooms, and exterior siding across Northern, Central, and Southern California. With a commitment to excellence and energy-efficient solutions, Northwest Exteriors enhances the beauty, comfort, and value of homes, delivering superior craftsmanship and exceptional customer service.

Media Contact
Company Name: Northwest Exteriors
Contact Person: Meredith Evans
Email: Send Email
Address:11200 Sun Center Dr
City: Rancho Cordova
State: California
Country: United States
Website: https://northwestexteriors.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Northwest Exteriors Encourages Homeowners to Upgrade with High-Performance Replacement Windows

MedVi Expands Access to GLP-1 Medication – Compounded Semaglutide for Healthy Living

The GLP-1 medication program by MedVi is now available nationwide starting at $179.

NEWARK, DE – MedVi Wellness, a leading telehealth provider in medical weight management, has announced the launch of its nationwide GLP-1 medication program, providing compounded semaglutide in both injectable and oral forms. Starting at $179 per month with no insurance required, MedVi offers an affordable, physician-guided alternative to high-cost brand-name drugs such as Wegovy® and Ozempic®.

The GLP-1 medication program combines compounded semaglutide with continuous clinical oversight, 24/7 support, and fast delivery, giving patients an accessible path to sustainable weight loss backed by medical expertise.

GLP-1 Medications Driving a New Era in Weight Management

Semaglutide, a GLP-1 receptor agonist, works by reducing appetite, improving satiety, and stabilizing blood sugar levels. Clinical studies show that GLP-1 medications can help patients achieve 15–18% average weight reduction over time when combined with healthy lifestyle changes.

“GLP-1 medications like semaglutide have redefined medical weight loss,” said a MedVi Wellness spokesperson. “By offering compounded semaglutide at an affordable price point with physician oversight, we are eliminating the barriers that keep most patients from accessing this transformative therapy.”

Key Features of MedVi’s GLP-1 Medication Program

Compounded Semaglutide Injections – Once-weekly dosing with pre-filled pens
Oral Semaglutide Tablets – A non-injectable option for daily use
Physician-Supervised Treatment – Personalized dosing plans from board-certified providers
Continuous Monitoring and Support – Unlimited check-ins and 24/7 medical access
Fast, Nationwide Delivery – Temperature-controlled shipping direct to patients

MedVi’s program also includes GLP-1 medication for blood sugar control, benefiting patients managing type 2 diabetes while addressing weight and metabolic health together.

Addressing Drug Shortages and Rising Demand

Due to ongoing shortages of brand-name GLP-1 drugs like Wegovy® and Ozempic®, compounded semaglutide has become a vital alternative. MedVi sources exclusively from FDA-regulated, PCAB-accredited compounding pharmacies, ensuring pharmaceutical-grade standards and verified potency.

“By combining GLP-1 medication expertise with streamlined telehealth delivery, MedVi is meeting demand where traditional healthcare has fallen short,” the spokesperson added. “Patients no longer need to wait months or pay thousands for care.”

Why MedVi?

GLP-1 medications starting at $179/month
FDA-regulated compounding facilities and U.S.-licensed physicians
Transparent, no-membership pricing
Money-back guarantee with ongoing medical guidance
Service availability in all 50 U.S. states

How It Works

Online Medical Evaluation: Complete a secure health assessment at medvi.io.
Physician Review: A board-certified provider approves treatment if medically appropriate.
Medication Delivery: GLP-1 medication ships directly to the patient’s home, with instructions included.
Ongoing Support: MedVi provides unlimited consultations, dose adjustments, and 24/7 access to licensed clinicians.

About MedVi Wellness

MedVi Wellness is a U.S.-based telehealth platform dedicated to weight loss and metabolic care through GLP-1 medications. By pairing clinical expertise with convenience and affordability, MedVi empowers patients to achieve lasting health results with doctor-led guidance and transparent pricing.

Media Contact
Company Name: MedVi Wellness
Contact Person: Media Relations
Email: Send Email
Phone: (323) 690-1564
Address:131 Continental Dr. Ste 305
City: Newark
State: DE 19713
Country: United States
Website: medvi.io

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MedVi Expands Access to GLP-1 Medication – Compounded Semaglutide for Healthy Living

Vows & Beyond Lets Couples Marry Online with Licensed Virtual Officiants

In an era defined by global love stories, digital lifestyles, and logistical challenges, Vows & Beyond has officially launched as a bold new service transforming the way couples get married. By enabling couples to legally tie the knot online, this groundbreaking platform eliminates the need for courthouse visits, travel, or complicated paperwork, making meaningful, heartfelt weddings accessible in just a few clicks.

Vows & Beyond offers a fully legal, personalized, and virtual wedding experience, anywhere in the world. Through its streamlined process and partnership with the state of Utah, couples can receive a valid U.S. marriage certificate, recognized in all 50 states and many countries internationally.

“With remote lifestyles, global love stories, and simplified legal needs on the rise, Vows & Beyond is answering the call for a simple, fast, and heartfelt way to get married from anywhere,” a company spokesperson shared.

A Modern Alternative to Traditional Weddings

Whether for love, immigration, elopement, military deployment, or sheer convenience, Vows & Beyond offers an affordable, stress-free solution that brings couples together legally and emotionally, even if they’re worlds apart.

Real-time ceremonies are conducted via Zoom or a preferred video platform, with licensed officiants leading couples through their vows. The process is fast, smooth, and deeply personal, complete with digital and physical marriage certificates, optional guest participation, and full video recordings.

“We got married from two different continents,” said the couple, Camila and Jordan. “My partner was in Brazil, and I was in the U.S. The process was smooth, legal, and surprisingly emotional. We both cried during the ceremony. Now we’re officially married, even while apart.”

How It Works: A 3-Step Online Wedding Journey

Step 1: Schedule a Ceremony

Couples select a date and time via an intuitive online calendar, with flexible booking available seven days a week.

Step 2: Complete the Application

After scheduling, both partners fill out a secure Utah marriage license application in just 10–20 minutes, providing valid government-issued IDs.

Step 3: Say “I Do” Virtually

On the selected day, couples join their officiated ceremony via video. A digital marriage certificate is issued instantly, with a certified physical copy mailed within days.

Key Features of Vows & Beyond

100% Legal Marriages: Recognized in all 50 U.S. states and over 150 countries
Global Accessibility: Ideal for international couples, military partners, and digital nomads
Customization: Personal vows, virtual backgrounds,and guest participation
Fast Turnaround: Marry in as little as 24–72 hours
All-Inclusive Pricing: No hidden fees; packages start at just $249
Expert Support: Full guidance from booking to certificate delivery

A Game-Changer for Cross-Border, Same-Gender, Civil, and Destination Marriages

Vows & Beyond serves all types of unions, from international weddings and civil partnerships to same-gender marriages and spontaneous elopements. With its fully inclusive approach, the platform has already helped thousands of couples unite legally and joyfully, regardless of distance or circumstance.

Limited-Time Launch Offer: Save $200

To celebrate the launch and honor love in all forms, Vows & Beyond is offering $200 off all wedding packages booked this month. With packages now starting at just $249, it’s never been more affordable to create a memorable, meaningful, and legal wedding from anywhere.

“This isn’t just a service; it’s a solution to one of life’s most meaningful moments,” a company representative added. “We’re proud to offer couples a way to celebrate their commitment with ease, legality, and heart.”

Real Love. Real Stories. Real Results.

Each month, hundreds of couples trust Vows & Beyond for their most intimate milestone. From immigration-challenged relationships to spontaneous unions and virtual destination weddings, Vows & Beyond is rewriting the rules of matrimony for the digital age.

Media Contact
Company Name: Vows and Beyond
Contact Person: Wayne Marshall
Email: Send Email
City: Charlotte
State: NC
Country: United States
Website: vowsnbeyond.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vows & Beyond Lets Couples Marry Online with Licensed Virtual Officiants

Omen Kaine Reimagines Poe’s Madness in Bold New Theater Play, The Heart Tells Tales

A dark, pandemic-era thriller blending psychological drama, live experimental music, and the haunting spirit of Edgar Allan Poe.

Los Angeles, CA, USA – July 30, 2025 – Prepare to be haunted in a whole new way. This fall, acclaimed playwright Omen Kaine unveils The Heart Tells Tales, a gripping, genre-defying adaptation inspired by Edgar Allan Poe’s The Tell-Tale Heart. Set against the eerie silence of pandemic-era Boston, the play dares to look deeper into the psychological toll of caregiving, isolation, and suppressed trauma.

The Heart Tells Tales is the second chapter in Kaine’s visionary Through the Altered Lens Trilogy—and this installment does not hold back. The story begins when neighbors of a revered, old-school musician report bloodcurdling screams. Police discover a horrifying crime scene—what appears to be domestic violence. But this is no marital dispute: the culprit is a young caregiver who confesses to murdering the older musician in his care. While the case seems open and shut, something doesn’t quite add up. The truth, like Poe’s original tale, may be more twisted than anyone can imagine.

Blending gritty storytelling with live original music, the production features an electrifying score by The Clandestine Circle Quintet, an experimental Los Angeles-based group whose sound fuses hip hop, rock, and jazz. The music doesn’t just underscore the narrative—it becomes part of its pulse, intensifying the suspense as the plot unfolds.

Hi Fi Underground is the production company bringing this powerful story to life. The company is dedicated to producing the theatrical works of Omen Kaine, a boundary-pushing voice in modern theater. For a short time, Kaine lived in a part of South Central L.A. known as the Jungle. On February 9, 1971 at 6:01 AM PST, a devastating M6.6 earthquake struck the Los Angeles metro area. Shortly after, his family moved back to Boston, where Kaine spent much of his formative years. He later attended high school in Concord, Massachusetts, where the transcendentalists once roamed.

From the 1990s through the early 2000s, Kaine traveled the U.S. and abroad, creating music and visual art. He later studied the arts at New York University and published his first novella, A Darker Nature, in 2003. His second publication was the illustrated play/graphic novel That Bookstore in the Alley. His first theatrical production, Masoch and Desade, debuted on Theater Row in Los Angeles (2019) and later played in Brooklyn, New York (2022). Now, he returns with his latest and most ambitious work yet: The Heart Tells Tales.

Produced by Hi Fi Underground Production, the show opens in Los Angeles October 23–25, 2025 at Skiptown Playhouse (665 Heliotrope Dr, Los Angeles, CA 90004), followed by a New York run November 21–23, 2025 at Under St. Marks Theater (94 Saint Marks Place, New York, NY 10009).

Tickets for the Los Angeles show are available now at:

https://www.eventbrite.com/e/the-heart-tells-tales-tickets-1543121069659

Tickets for the New York show are also available at:

https://www.eventbrite.com/e/the-heart-tells-tales-tickets-1474594123719

“This is not just a play. It’s a reckoning,” says Omen Kaine. “We’re looking through the eyes of trauma, guilt, and the blurred lines of morality—and amplifying it with sound and soul.”

An international tour stop in Belgium is also slated for winter 2026.

SHOW DATES & LOCATIONS

LOS ANGELES

Skiptown Playhouse

665 Heliotrope Dr, Los Angeles, CA 90004

October 23–25, 2025 | 7:30 PM – 10:00 PM PST

Purchase Tickets

NEW YORK CITY

Under St. Marks Theater

94 Saint Marks Place, New York, NY 10009

November 21–23, 2025 | 7:00 PM – 9:30 PM EST

Purchase Tickets

Follow updates and behind-the-scenes sneak peeks:

* Instagram @hifiundergroundshop : https://www.instagram.com/hifiundergroundshop

* Facebook: https://www.facebook.com/profile.php?id=100064267262382

For media inquiries, interviews, or press passes, please contact:

Domenick Nati

Nati Celebrity Services

DNati[at]NatiCelebs[dot]com

Media Contact
Company Name: Nati Celebrity Services, Inc.
Contact Person: Domenick Nati
Email: Send Email
Country: United States
Website: www.naticelebs.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Omen Kaine Reimagines Poe’s Madness in Bold New Theater Play, The Heart Tells Tales

Importivity Facilitates Record-Breaking Growth in Clients Buying in Bulk from China, Countering Media Narrative of U.S.-China Trade Decline

Austin, TX – July 30, 2025 – In direct contrast to prevalent media reports claiming U.S.-China trade relations are deteriorating, Importivity, a leading global sourcing and logistics consulting firm based in Austin, Texas, today announced a remarkable 422% year-over-year increase in bulk imports from China for their U.S. clients during the second quarter of 2025.

While mainstream headlines frequently discuss the negative impact of tariffs and trade uncertainties, Importivity’s clients have strategically leveraged current conditions to substantially grow their inventory positions. “We’ve seen a substantial uptick in businesses proactively buying in bulk from China,” explains Jordan Lewis, Chief Operating Officer at Importivity. “While some of this growth naturally correlates with our clients’ own expansion and market success, much of it reflects a savvy, strategic effort to capitalize on the current tariff pause. Companies recognize this moment as a golden window of opportunity to secure inventory at reasonable duty rates and buy themselves critical time to diversify their sourcing strategies.

Importivity’s CEO and COO at the 2025 Canton Fair in Guangzhou, China.

“Lewis highlights how the first quarter of 2025 presented significant challenges, stating: “Q1 hit our clients hard. Businesses were understandably nervous, prompting frantic calls about supply chain strategies and tariff impacts. Fortunately, at Importivity, we anticipated these scenarios as early as November of last year and developed detailed, customized contingency plans for each client. We even made strategic investments in partner facilities in Vietnam to offer trusted alternatives and diversify our clients’ supply chain networks.”

The firm’s comprehensive strategy notably paid off for numerous clients. For example, Importivity recently assisted a client who had over $2 million worth of taxable goods stuck in transit at Long Beach port. Leveraging expert compliance knowledge, Importivity swiftly identified and filed under relevant legal exemptions, including HTSUS Chapter 98 (U.S. Goods Returned) and Section 321 de minimis entries, resulting in substantial cost savings and rapid cargo clearance, a major relief to the client’s supply chain operations.

Deedee Patterson, founder of Whiskey Towers, an innovative liquor dispenser brand and Importivity client, directly challenges popular negative narratives regarding tariffs: “Our business has experienced no significant negative impact from tariffs. Yes, we’ve noticed some incremental increases in product costs, but our margins remain strong due to dramatically increased sales volumes. Frankly, the strength of consumer demand more than offsets these incremental tariff-related costs. To us, this signals a very healthy, robust economy, not a struggling one.”

Lewis describes the second quarter of 2025 as transformational: “Closing Q2 feels akin to stepping off a roller coaster. After a challenging Q1, we saw unprecedented record imports from China. The tariff pause has given our clients a critical advantage, enabling them to stockpile inventory effectively and granting them the breathing room necessary to formulate robust long-term sourcing strategies.” Expressing cautious optimism about future U.S.-China trade relations, Lewis notes: “I’m genuinely optimistic that the United States and China will ultimately reach a mutually beneficial trade agreement. Still, at Importivity, we never rely solely on optimism—we encourage our clients to act strategically. Smart businesses are making bold moves today, proactively securing inventory and diversifying their sourcing to stay ahead of any future trade disruptions.”

About Importivity

Importivity is a premier global sourcing and logistics firm dedicated to simplifying and optimizing international procurement processes. Specializing in helping U.S. brands securely navigate the complexities of buying in bulk from China, Vietnam, and Mexico, Importivity offers customized solutions in product sourcing, compliance, tariff mitigation, quality assurance, and streamlined logistics.

Brands interested in learning how they can secure their inventory, mitigate risks, and explore global sourcing opportunities are encouraged to schedule a complimentary strategy call at: https://book.bizeebay.com/#/importivity-consultation

For further details about Importivity’s China sourcing capabilities, please visit: https://importivity.com/connections/buying-in-bulk-from-china/

Media Contact
Company Name: Importivity LLC
Contact Person: Lila Monroe – Head of Communications
Email: Send Email
Phone: +1 (877) 570-6930
Country: United States
Website: https://importivity.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Importivity Facilitates Record-Breaking Growth in Clients Buying in Bulk from China, Countering Media Narrative of U.S.-China Trade Decline

Top Realtor in Kirkland, WA, Secures Strong Backing from Local Leaders Ahead of City Council Election

Kirkland, WA – Gina Madeya, candidate for Kirkland City Council Position 3, has secured the endorsement of a diverse coalition of respected community leaders, unions, and organizations, underscoring the growing momentum behind her grassroots campaign.

The Kirkland Firefighters Union has thrown its support behind Gina, a trusted Realtor in Kirkland, WA, recognizing her commitment to public safety, responsible planning, and unwavering support for first responders.

The Eastside Business Alliance has praised Gina Madeya for her forward-thinking approach to local economic vitality and small business development.

State Representative Amy Walen, former Kirkland Mayor and long-time community advocate, has endorsed Gina as a proven leader who understands how to move Kirkland forward with care and collaboration. As a Kirkland, WA Realtor and City Planning Commissioner, Gina brings unique perspective on development policies that balance growth with neighborhood character preservation.

The Amalgamated Transit Union (ATU) has announced its support for Gina Madeya for her strong advocacy of multimodal transportation options and better access to transit for all residents. Additionally, Gina is proud to be backed by key neighborhood leaders, including board members from Finn Hill and Evergreen Hill/Kingsgate, along with two Kirkland Human Services Commissioners who value her commitment to supporting youth, seniors, and vulnerable neighbors.

“I’m deeply honored to have the trust and support of so many people who are working every day to make Kirkland stronger, from our firefighters and transit workers to local business leaders and neighborhood advocates,” said Gina Madeya. “Their endorsements reflect the heart of this campaign: putting people and community first.”

For those seeking a dedicated advocate who understands both real estate and community development, Gina Madeya offers proven leadership and results. Visit https://www.electginamadeya.com/ today to learn more about her vision for Kirkland’s future and her commitment to serving the community with integrity and transparency. With the August 5th election approaching, voters are encouraged to support a candidate who brings both professional expertise and genuine community dedication to City Council.

Media Contact
Company Name: Gina Madeya | Real Estate Agent in Kirkland WA
Contact Person: Media Relations
Email: Send Email
Phone: +1 (425) 495-0926
Address:3933 Lake Washington Blvd NE suite 100
City: Kirkland
State: Washington 98033
Country: United States
Website: https://www.ginamadeya.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Realtor in Kirkland, WA, Secures Strong Backing from Local Leaders Ahead of City Council Election

Chimeric Antigen Receptor T-Cell Therapy Pipeline Outlook Report 2025: Key 180+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chimeric Antigen Receptor T-Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Chimeric Antigen Receptor T-Cell Therapy Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Chimeric Antigen Receptor T-Cell Therapy Pipeline Outlook Report

Key Takeaways from the Chimeric Antigen Receptor T-Cell Therapy Pipeline Report

In July 2025, Janssen Research & Development LLC announced a study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
In July 2025, Adicet Therapeutics conducted a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 – an Engineered gamma-delta Chimeric Receptor [CAR] Vδ1 T Cell product Targeting CD70 – in patients with R/R ccRCC.
In July 2025, AstraZeneca organized a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
DelveInsight’s Chimeric Antigen Receptor T-Cell Therapy pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Chimeric Antigen Receptor T-Cell Therapy treatment.
The leading Chimeric Antigen Receptor T-Cell Therapy Companies such as Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.
Promising Chimeric Antigen Receptor T-Cell Therapy Pipeline Therapies such as Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.

Discover how the Chimeric Antigen Receptor T-Cell Therapy treatment paradigm is evolving. Access DelveInsight’s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chimeric Antigen Receptor T-Cell Therapy Clinical Trials and Studies

Chimeric Antigen Receptor T-Cell Therapy Emerging Drugs Profile

Descartes-08: Cartesian Therapeutics

Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA) that utilizes a novel modality and mechanism of action for treating gMG and other autoimmune diseases. Descartes-08 differs from anti-B-cell agents, which do not address long-lived plasma cells, and differs from FcRn blockers or complement inhibitors, which attempt to intervene only after autoantibodies are produced and pathogenic mediators are amplified. Descartes-08 is intended to halt production of autoantibodies by targeting pathogenic long-lived plasma cells with the potential to survive for decades within the body. Currently, the drug is in the Phase II stage of its development for the treatment of Myasthenia gravis (gMG).

CART-ddBCMA: Arcellx, Inc

CART-ddBCMA is a genetically modified cell therapy utilizing a novel synthetic binding domain that is computationally designed, highly stable, and engineered to reduce immunogenicity. CART-ddBCMA is a Phase I study of Arcellx’s BCMA-specific CAR-modified T-cell therapy utilizing the company’s novel BCMA-targeting binding domain for the treatment of patients with relapsed and refractory multiple myeloma. The Arcellx ddBCMA cell therapy has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration. The Phase I study is currently enrolling patients. CART-ddBCMA was well tolerated and rapid, deep, and durable responses were observed at the first dose level of 100 million cells, with six of six evaluable patients responding per IMWG criteria. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple myeloma.

NXC-201: Nexcella, Inc

NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. NXC-201 (formerly HBI0101) is the only “Single-Day CRS” CAR-T cell therapy that is uniquely suited to target AL Amyloidosis and other autoimmune diseases. It is being studied in a comprehensive clinical development program for the treatment of patients with relapsed/refractory AL amyloidosis, and expanding into other autoimmune indications. These trials build on a robust NXC-201 clinical dataset initiated in February 2021. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and awarded EU ODD by the EMA in AL Amyloidosis. Currently, the drug is in the Phase I/II stage of its development for the treatment of AL Amyloidosis and multiple myeloma.

AUTO-8: Autolus Therapeutics

AUTO8 is the next-generation product candidate for multiple myeloma which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. The company have developed an optimized BCMA CAR which is designed for improved killing of target cell that express BCMA at low levels. This has been combined with fast off rate CD19 CAR from obe-cel the company believes that the design of AUTO8 has the potential to induce deep and durable responses and extend the durability of effect over other BCMA CARs currently in development. Currently, the drug is in the Phase I stage of its development for the treatment of multiple myeloma.

SG299: Sana Biotechnology

SG299, is the first drug candidate from the fusogen platform, in generating CD19-directed CAR T cells with in vivo delivery. In 2023, look forward to initial clinical data for SC291, allogeneic CAR T cells for patients with B cell cancers; filing an IND for SC262, allogeneic CAR T cells for patients that have failed previous CAR T therapy and filing an IND for SG299, in vivo CAR delivery program for patients with B cell cancers. Currently, the drug is in the Preclinical stage of its development for the treatment of chronic lymphocytic leukemia

The Chimeric Antigen Receptor T-Cell Therapy pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chimeric Antigen Receptor T-Cell Therapy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chimeric Antigen Receptor T-Cell Therapy Treatment.
Chimeric Antigen Receptor T-Cell Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chimeric Antigen Receptor T-Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chimeric Antigen Receptor T-Cell Therapy market.

Get a detailed analysis of the latest innovations in the Chimeric Antigen Receptor T-Cell Therapy pipeline. Explore DelveInsight’s expert-driven report today! @ Chimeric Antigen Receptor T-Cell Therapy Unmet Needs

Chimeric Antigen Receptor T-Cell Therapy Companies

Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Chimeric Antigen Receptor T-Cell Therapy Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key Thyroid Cancer Developments @ Chimeric Antigen Receptor T-Cell Therapy Market Drivers and Barriers, and Future Perspectives

Scope of the Chimeric Antigen Receptor T-Cell Therapy Pipeline Report

Coverage- Global
Chimeric Antigen Receptor T-Cell Therapy Companies- Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.
Chimeric Antigen Receptor T-Cell Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
Chimeric Antigen Receptor T-Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chimeric Antigen Receptor T-Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Chimeric Antigen Receptor T-Cell Therapy drug development? Find out in DelveInsight’s exclusive Pipeline Report—access it now! @ Chimeric Antigen Receptor T-Cell Therapy Emerging Drugs and Major Companies

Table of Contents

Introduction
Executive Summary
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) : Overview
Pipeline Therapeutics
Therapeutic Assessment
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company Name
Mid Stage Products (Phase II)
Descartes-08: Cartesian Therapeutics
Early Stage Products (Phase I/II)
NXC-201: Nexcella, Inc
Preclinical and Discovery Stage Products
SG299: Sana Biotechnology
Drug profiles in the detailed report…..
Inactive Products
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Products
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) – Unmet Needs
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) – Market Drivers and Barriers
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) – Future Perspectives and Conclusion
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Analyst Views
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chimeric Antigen Receptor T-Cell Therapy Pipeline Outlook Report 2025: Key 180+ Companies and Breakthrough Therapies Shaping the Future Landscape

ER+/HER2− Breast Cancer Market: Epidemiology, Pipeline Products, Companies Working, DelveInsight | KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant,

“ER+/HER2? Breast Cancer Market”

DelveInsight’s “ER+/HER2− Breast Cancer – Market Insights, Epidemiology and Market Forecast– 2034” report delivers an in-depth understanding of the ER+/HER2− Breast Cancer, historical and forecasted epidemiology as well as the ER+/HER2− Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Emerging therapies for ER+/HER2− breast cancer—such as KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171/GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and several others—are anticipated to drive significant growth in the ER+/HER2− breast cancer market in the coming years.

DelveInsight has launched a new report on “ER+/HER2− Breast Cancer – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the ER+/HER2− Breast Cancer, historical and forecasted epidemiology as well as the ER+/HER2− Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover latest insights into our ER+/HER2- Breast cancer market report https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the ER+/HER2− Breast Cancer Market Report:

In 2021, the total number of new breast cancer cases in the United States was 256,431. Among these, postmenopausal breast cancer accounted for 205,145 cases. In the same year, the distribution of breast cancer cases by stage was as follows: 164,116 localized, 74,365 regional, 15,386 distant, and 2,564 with unknown stage. These numbers are expected to rise during the forecast period.
Among the various subtypes of the disease (localized and regional), ER+/HER2− represented the largest patient group with 147,977 cases, followed by 24,325 cases of triple-negative breast cancer and 20,271 cases of ER+/HER2+. Conversely, HR−/HER2+ had the fewest cases.
Key ER+/HER2− Breast Cancer companies such as Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others are evaluating new drugs for ER+/HER2− Breast Cancer to improve the treatment landscape.
Promising ER+/HER2− Breast Cancer pipeline therapies in various stages of development include KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others.

Key benefits of the ER+/HER2− Breast Cancer market report:

ER+/HER2− Breast Cancer market report covers a descriptive overview and comprehensive insight of the ER+/HER2− Breast Cancer Epidemiology and ER+/HER2− Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The ER+/HER2− Breast Cancer market report provides insights on the current and emerging therapies.
ER+/HER2− Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The ER+/HER2− Breast Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the ER+/HER2− Breast Cancer market.

Got queries? Click here to know more about the ER+/HER2− Breast Cancer Market Landscape

ER+/HER2− Breast Cancer Overview

Breast cancer arises when abnormal cells in the breast grow and divide uncontrollably, eventually forming a tumor. It usually originates in the ducts or lobules of the breast and may be driven by various growth signals, including hormones.

Hormone receptors are proteins on cancer cells that recognize hormone signals and trigger cell growth. When breast cancer cells respond to estrogen, it’s called estrogen receptor-positive (ER+) breast cancer. If they respond to progesterone, it’s progesterone receptor-positive (PR+). Cancers that are ER+ and/or PR+ are grouped under hormone receptor-positive (HR+) breast cancer.

Conversely, hormone receptor-negative (HR−) breast cancer lacks these receptors and doesn’t depend on estrogen or progesterone to grow.

Another important factor is the human epidermal growth factor receptor 2 (HER2), a protein involved in cell growth and repair. HER2-positive (HER2+) breast cancers have high levels of this protein and tend to grow faster and have a higher risk of spreading or returning. HER2 status is identified through testing.

HER2-negative (HER2−) breast cancers have low or no HER2 protein expression. These cancers generally grow more slowly and are less likely to spread than HER2+ types. Determining HER2 status is essential for guiding appropriate treatment.

ER+/HER2− Breast Cancer Treatment Market

Estrogen receptor (ER) expression plays a critical role in determining how well hormonal therapies will work, as the majority of breast cancers are hormone-dependent and ER-positive. Treatment options for patients with early-stage, advanced, or metastatic breast cancer include various anti-estrogenic therapies such as selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs).

Current clinical research is increasingly focused on enhancing the effectiveness of these therapies by combining them with targeted agents that inhibit the PI3K/AKT/mTOR signaling pathway or the CDK4/6 pathway, which controls the G1/S cell cycle checkpoint. These combinations are being explored particularly for hormone receptor-positive breast cancer patients who have experienced disease progression or recurrence.

Discover how the ER+/HER2- Breast cancer treatment market is growing

ER+/HER2− Breast Cancer Market Outlook

Breast cancer ranks as the second most commonly diagnosed cancer worldwide, with estrogen receptor-positive (ER+) breast cancer being the most frequent subtype. Roughly two-thirds of all breast cancer cases are hormone receptor-positive (HR+), predominantly ER+, meaning they are fueled by estrogen, which promotes tumor growth.

The stage at diagnosis greatly influences treatment strategy. In Stages I to III, surgery is typically the first-line treatment, often followed by radiation. Depending on hormone receptor and HER2 status, additional therapies may include chemotherapy, hormone therapy (such as tamoxifen or aromatase inhibitors), and HER2-targeted drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta). For early-stage HR+ breast cancer (Stage I), hormone therapy is usually sufficient, while larger tumors might also require chemotherapy. HER2-positive tumors are treated with HER2-directed therapies.

In Stage II, systemic treatments—either before (neoadjuvant) or after surgery (adjuvant)—are commonly used. Neoadjuvant therapies can reduce tumor size to allow for breast-conserving surgery. Stage III cancers often need neoadjuvant chemotherapy, and HER2-targeted therapies are added when appropriate.

Treatment options include tamoxifen, aromatase inhibitors (letrozole, anastrozole, exemestane), luteinizing hormone-releasing hormone analogs (goserelin, leuprolide), and fulvestrant, especially in cases of resistance. Patients typically receive sequential hormone therapies until resistance emerges, at which point chemotherapy is considered.

The ER+/HER2− breast cancer pipeline features a number of promising therapies in mid-to-late stages of development. Companies like Radius Pharmaceuticals (Elacestrant), AstraZeneca (Camizestrant), and Roche (Giredestrant) are actively developing innovative treatments that could transform the therapeutic landscape in the near future.

Explore more about ER+/HER2- Breast cancer market

ER+/HER2− Breast Cancer Marketed Drugs:

KISQALI (ribociclib): Novartis
IBRANCE (palbociclib): Pfizer
AFINITOR (everolimus): Novartis
LYNPARZA (olaparib): AstraZeneca

ER+/HER2− Breast Cancer Emerging Drugs:

Elacestrant: Radius Pharmaceuticals
Giredestrant (RG6171, GDC-9545): Roche
Camizestrant (AZD9833): AstraZeneca
LY3484356 (imlunestrant): Eli Lilly
Lerociclib (EQ132): EQRx

Discover which ER+/HER2- Breast cancer drugs will boost the market in the upcoming years

Scope of the ER+/HER2− Breast Cancer Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key ER+/HER2− Breast Cancer Companies: Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others
Key ER+/HER2− Breast Cancer Therapies: KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others
ER+/HER2− Breast Cancer Therapeutic Assessment: ER+/HER2− Breast Cancer current marketed and ER+/HER2− Breast Cancer emerging therapies
ER+/HER2− Breast Cancer Market Dynamics: ER+/HER2− Breast Cancer market drivers and ER+/HER2− Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
ER+/HER2− Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, ER+/HER2− Breast Cancer Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. ER+/HER2− Breast Cancer Patient Share (%) Overview at a Glance

5. ER+/HER2− Breast Cancer Market Overview at a Glance

6. ER+/HER2− Breast Cancer Disease Background and Overview

7. ER+/HER2− Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of ER+/HER2− Breast Cancer

9. ER+/HER2− Breast Cancer Current Treatment and Medical Practices

10. Unmet Needs

11. ER+/HER2− Breast Cancer Emerging Therapies

12. ER+/HER2− Breast Cancer Market Outlook

13. Country-Wise ER+/HER2− Breast Cancer Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. ER+/HER2− Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

ER+/HER2− Breast Cancer Pipeline Insights, DelveInsight

“ER+/HER2− Breast Cancer Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the ER+/HER2− Breast Cancer market. A detailed picture of the ER+/HER2− Breast Cancer pipeline landscape is provided, which includes the disease overview and ER+/HER2− Breast Cancer treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ER+/HER2− Breast Cancer Market: Epidemiology, Pipeline Products, Companies Working, DelveInsight | KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant,